What is the specific information about Guanfacine?

Guanfacine is a generic version independently developed by a domestic company. Its pharmaceutical name is Guanfacine Hydrochloride Sustained Release Tablets. It is a selective α-2A adrenergic receptor agonist, mainly used to treat attention deficit hyperactivity disorder (ADHD) in children and adolescents. The core mechanism of the drug is to regulate the synaptic activity of neurons in the prefrontal cortex, thereby improving concentration and inhibiting impulsive behavior. Although its exact mechanism is still under study, foreign studies have confirmed that its role in the central nervous system is closely related to the dopamine and norepinephrine neural pathways.

Baili Tianheng’s domestic R&D layout reflects the strategy of both innovation and substitution. In the global ADHD drug landscape, the proportion of non-stimulant drugs is increasing year by year. Compared with traditional stimulants, guanfacine does not affect sleep quality and has relatively little interference with heart rate and blood pressure. It is suitable for patients who are intolerant to stimulant drugs or have anxiety disorders. The introduction of domestic generic drugs will not only help fill the treatment gap, but also significantly reduce the cost of household medication and expand drug accessibility.

From the perspective of pharmacological characteristics, the sustained-release dosage form of guanfacine can achieve stable blood concentration for 24 hours and avoid behavioral fluctuations caused by peak and valley effects. It has excellent performance in medication compliance and adverse reaction control. Bailey Tianheng pays attention to the consistency evaluation of preparations during the generic development process, and strives to make the domestic version meet international standards in terms of bioequivalence.

Currently, the drug is still in the registration review stage, but the industry generally expects that it will become an important addition to the field of non-stimulant treatment for ADHD once it is launched. As the country pays more attention to children's mental health, the market space of Balitian Guanfacine will continue to expand, which also represents a key step for China to gradually narrow the gap with the international market in the field of central nervous system regulation drugs.

Reference materials:https://go.drugbank.com/drugs/DB01018